Levomenol

Levomenol

SCHEMBL4259122

CC(C)=CCCC(C)(O)[C@H]1CC=C(C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 1.00
CYP3A4 P08684 2/20 1.00
STAT3 P40763 2/20 1.00
MEN1 O00255 1/20 1.00
MAPK1 P28482 1/20 1.00
KMT2A Q03164 1/20 1.00
CHRNA7 P36544 1/20 1.00
LMNA P02545 3/20 0.65
PTPN1 P18031 3/20 0.65
CES2 O00748 2/20 0.38
ESR1 P03372 2/20 0.33
HIF1A Q16665 1/20 0.33
EPAS1 Q99814 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levomenol SCHEMBL12414344 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL24988 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL2728600 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL24989 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL31157846 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL14515491 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Bisabolol SCHEMBL13220166 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL1245143 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL20838984 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1
Levomenol SCHEMBL172398 1.00 ALOX15 (1.00) ALOX15CYP3A4STAT3MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090169652-A1 Personal Care Compositions THE PROCTER & GAMBLE COMPANY 2009-07-02 US claimed
US-20230338250-A1 Compositions Comprising One or More (Bio)-Alkanediols with Active Ingredients SYMRISE AG (DE) 2023-10-26 US disclosed
US-20200206231-A1 TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA BIOLAB SANUS FARMACEUTICA LTDA (BR) 2020-07-02 US disclosed
US-20140299149-A1 COMPOSITIONS AND METHODS FOR TREATING KERATIN BASED FIBERS COOLWAY INC (US) 2014-10-09 US disclosed
US-20090169652-A1 Personal Care Compositions THE PROCTER & GAMBLE COMPANY 2009-07-02 US disclosed
US-20050025847-A1 Microbicidal compositions and method of use PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (US) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200206231-A1 TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA MTX1, MTX2, IL17A ALOX15 352/4885CYP3A4 499/4885STAT3 2751/4885
US-20090169652-A1 Personal Care Compositions CUTA, C5, F7 ALOX15 370/4885CYP3A4 4006/4885STAT3 4420/4885
US-20230338250-A1 Compositions Comprising One or More (Bio)-Alkanediols with Active Ingredients DERL1, DHCR7, DHCR24 ALOX15 143/4885CYP3A4 1783/4885STAT3 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.